Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
The FDA has approved the drug pembrolizumab to treat patients with advanced non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1.
-
A recent NCI-sponsored conference brought together leading screening and cancer control researchers to discuss the state of the science of precision screening for five cancers.
-
A new study has found that patients with annual household incomes below $50,000 were less likely to participate in a cancer clinical trial than those with higher incomes.
-
Metastatic tumor cells are particularly sensitive to oxidative stress, and antioxidant supplementation increases their ability to grow and metastasize.
-
The FDA has approved nivolumab in combination with ipilimumab for advanced melanoma and nivolumab alone for advanced nonsquamous lung cancer.
-
Recognizing that complex factors underlie health disparities, NCI is taking a holistic approach in our efforts to address this serious public health issue.
-
Patients with advanced cancer may benefit from having discussions about their prognoses with their physicians.
-
A team of NCI researchers has reported that several types of gastrointestinal cancer have tumor-specific mutations that can be recognized by the immune system, thereby offering a new therapeutic opportunity for patients with these tumors.
-
A new approach to disrupting genes that promote the development and spread of tumors may hold promise for treating an aggressive and difficult-to-treat type of breast cancer.
-
A number of NCI programs and networks are the foundation of the National Cancer Program and play a critical role in promoting progress.